Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

被引：0
|
作者：
Ottmann, Oliver G. [1 ]
DeAngelo, Daniel J. [2 ]
Garcia-Manero, Guillermo [3 ]
Luebbert, Michael [4 ]
Jillella, Anand [5 ]
Sekeres, Mikkael A. [6 ]
Zahlten, Anita [7 ]
Squier, Margaret [8 ]
Acharyya, Suddhasatta [8 ]
Winiger, Ivo J. [7 ]
Fenaux, Pierre [9 ]
机构：
[1] Goethe Univ Frankfurt, Dept Internal Med, Frankfurt, Germany
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Freiburg, D-79106 Freiburg, Germany
[5] Georgia Hlth Sci Univ, Augusta, GA USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Hop Avicenne, AP HP, F-93009 Bobigny, France
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：212 / 213
页数：2
相关论文
共 50 条
  • [41] Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
    Helbig, Grzegorz
    Chromik, Karolina
    Wozniczka, Krzysztof
    Kopinska, Anna J.
    Boral, Kinga
    Dworaczek, Martyna
    Koclega, Anna
    Armatys, Anna
    Panz-Klapuch, Marta
    Markiewicz, Miroslaw
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (03) : 1175 - 1180
  • [42] SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATMENT WITH 5-AZACITIDINE: EXPERIENCE OF A CENTER
    Busnego, M. T.
    Sanchez, A.
    Notario, C.
    Cabello, A.
    Oliva, A.
    Brena, J.
    Alberich, M. P.
    Gonzalez, H.
    Marrero, C.
    Rios, P.
    Figueroa, A.
    Hernanz, N.
    Rios, M.
    Leon, A.
    Hernandez, P.
    Hillebrand, P.
    Uribe, L.
    Mesa, M. C.
    HAEMATOLOGICA, 2019, 104 : 424 - 424
  • [43] Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Chien, Kelly S.
    Valero, Yesid Alvarado
    Daver, Naval
    Borthakur, Gautam
    Swaminathan, Mahesh
    Maiti, Abhishek
    Hammond, Danielle E.
    Nogueras-Gonzalez, Graciela
    Huang, Xuelin
    Schneider, Heather
    Shelly, Kristen
    Kadia, Tapan M.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [44] Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review
    Thorpe, Michael
    Montalvao, Ana
    Pierdomenico, Francesca
    Moita, Filipa
    Almeida, Antonio
    LEUKEMIA RESEARCH, 2012, 36 (08) : 1071 - 1073
  • [45] PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Borate, U.
    Smith, B. D.
    Gore, S.
    Zeidan, A.
    Savona, M.
    Savoie, M. L.
    Zhu, N.
    Breems, D.
    Zhang, X.
    Shaik, M. N.
    Rampersad, A.
    Chan, G.
    Woolfson, A.
    Sekeres, M.
    HAEMATOLOGICA, 2016, 101 : 73 - 74
  • [46] A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
    Swaminathan, Mahesh
    Kantarjian, Hagop M.
    Levis, Mark
    Guerra, Veronica
    Borthakur, Gautam
    Alvarado, Yesid
    DiNardo, Courtney D.
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Daver, Naval
    Konopleva, Marina
    Pemmaraju, Naveen
    Ferrajol, Alessandra
    Andreeff, Michael
    Jain, Nitin
    Estrov, Zeev
    Jabbour, Elias J.
    Wierda, William G.
    Pierce, Sherry
    Pinsoy, Maria Rhona
    Xiao, Lianchun
    Ravandi, Farhad
    Cortes, Jorge E.
    HAEMATOLOGICA, 2021, 106 (08) : 2121 - 2130
  • [47] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
    Savona, M. R.
    Kolibaba, K.
    Conkling, P.
    Kingsley, E. C.
    Becerra, C.
    Morris, J. C.
    Rifkin, R. M.
    Laille, E.
    Kellerman, A.
    Ukrainskyj, S. M.
    Dong, Q.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
  • [48] Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Receiving Glasdegib plus Azacitidine
    Wang, Eunice
    Bell, Timothy
    Zeidan, Amer
    Bhattcharyya, Helen
    Kudla, Arthur
    Chan, Geoffrey
    Sekeres, Mikkael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S191 - S191
  • [49] Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Fraison, Jean-Baptiste
    Mekinian, Arsene
    Grignano, Eric
    Kahn, Jean-Emmanuel
    Arlet, Jean-Benoit
    Decaux, Olivier
    Denis, Guillaume
    Buchdahl, Anne-Laure
    Omouri, Mohamed
    Maigne, Gwenola
    Aouba, Achille
    Leon, Nathalie
    Berthier, Sabine
    Liozon, Eric
    Park, Sophie
    Gardin, Claude
    Lortholary, Olivier
    Rossignol, Julien
    Fenaux, Pierre
    Fain, Olivier
    Braun, Thorsten
    LEUKEMIA RESEARCH, 2016, 43 : 13 - 17
  • [50] A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia
    Kunacheewa, Chutima
    Thongthang, Pakaporn
    Ungprasert, Patompong
    Utchariyaprasit, Eakkapol
    Owattanapanich, Weerapat
    HEMATOLOGY, 2019, 24 (01) : 498 - 506
12345